在摩洛哥多发性硬化症患者中使用传统和补充医学
Rachid Lotfi1, Mourad Chikhaoui2, Abdessamad Elmourid3
1From the Biological Engineering Laboratory, Faculty of Sciences and Techniques, University Sultan Moulay Slimane, Bèni Mellal, Morocco.
International journal of MS care
|June 14, 2024
概括
超过一半的摩洛哥多发性硬化症 (MS) 患者使用传统和补充医学 (T&CM). 在进展性多发性硬化和缺乏传统疗法的人群中,T&CM的使用率更高.
科学领域:
- 神经学 神经学
- 补充医学是一种补充医学.
- 公共卫生 公共卫生
背景情况:
- 多发性硬化症 (MS) 是一种慢性,自身免疫性,神经退行性中枢神经系统疾病.
- 患有多发性硬化症的患者经常与传统治疗一起探索传统和补充医学 (T&CM).
- 了解T&CM利用对于MS患者的综合患者护理至关重要.
研究的目的:
- 描述在被诊断患有MS的摩洛哥患者队列中使用T&CM的模式.
- 为了确定与摩洛哥MS患者中T&CM利用相关的因素.
主要方法:
- 采用了定量描述性研究设计.
- 对98名多发性硬化症患者进行匿名电子问卷调查.
- 使用多变量分析来评估影响T&CM使用的因素.
主要成果:
- 在接受调查的多发性硬化症患者中,52%的人报告使用T&CM.
- 人气的T&CM模式包括杯子 (29.6%),古兰经诵读 (23.5%),植物疗法 (15.3%),阿皮疗法 (13.2%) 和针 (10.2%).
- 进展性多发性硬化症患者 (OR=2.54) 和没有资金可获得疾病修饰疗法的患者 (OR=2.10) 中,T&CM的使用量显著增加.
结论:
- 社会,文化和经济因素显著影响MS患者的T&CM使用.
- 需要进一步的研究来探索推动这一群体采用T&CM的具体动机.
- 将T&CM的见解融入到MS患者管理中可能会改善整体护理.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20


